While Tuesday’s results are from a mid-stage test, the stock market reaction indicates Wall Street sees it as a potential competitor to pneumococcal vaccines from Pfizer, Merck & Co. and GSK. Pfizer, ...
Emory researchers are the first to show unprecedented control of SIV replication and decay of viral reservoirs by combining a ...
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...